Stevanato Group S.p.A. (NYSE:STVN) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Stevanato Group S.p.A. (NYSE:STVN) have received an average rating of “Moderate Buy” from the six ratings firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company.

STVN has been the topic of several recent research reports. Morgan Stanley reaffirmed an “equal weight” rating and set a $23.00 target price (down from $24.00) on shares of Stevanato Group in a research note on Tuesday, December 3rd. Wolfe Research began coverage on Stevanato Group in a report on Friday, December 13th. They issued an “outperform” rating and a $28.00 target price on the stock. Finally, Bank of America increased their price objective on Stevanato Group from $24.00 to $26.00 and gave the company a “buy” rating in a report on Friday, December 13th.

Stevanato Group Stock Performance

Shares of Stevanato Group stock opened at €22.92 ($23.39) on Tuesday. Stevanato Group has a one year low of €16.56 ($16.90) and a one year high of €34.73 ($35.44). The company has a market cap of $6.77 billion, a price-to-earnings ratio of 48.77, a PEG ratio of 10.49 and a beta of 0.56. The business’s 50 day moving average price is €21.24 and its 200 day moving average price is €20.23. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.21 and a current ratio of 1.81.

Stevanato Group (NYSE:STVN) last released its quarterly earnings data on Tuesday, November 5th. The company reported €0.12 ($0.12) EPS for the quarter, missing analysts’ consensus estimates of €0.13 ($0.13) by (€0.01) (($0.01)). Stevanato Group had a net margin of 10.47% and a return on equity of 9.86%. The business had revenue of €277.90 million during the quarter, compared to analyst estimates of €274.36 million. During the same quarter in the prior year, the company posted $0.16 earnings per share. The company’s revenue was up 2.4% on a year-over-year basis. On average, research analysts predict that Stevanato Group will post 0.5 EPS for the current year.

Institutional Investors Weigh In On Stevanato Group

Large investors have recently modified their holdings of the company. Hardy Reed LLC raised its stake in Stevanato Group by 8.2% during the 3rd quarter. Hardy Reed LLC now owns 11,077 shares of the company’s stock valued at $222,000 after acquiring an additional 840 shares during the last quarter. Lindenwold Advisors INC raised its stake in shares of Stevanato Group by 13.5% during the third quarter. Lindenwold Advisors INC now owns 11,930 shares of the company’s stock worth $239,000 after purchasing an additional 1,415 shares during the last quarter. Captrust Financial Advisors lifted its holdings in shares of Stevanato Group by 12.7% during the third quarter. Captrust Financial Advisors now owns 13,100 shares of the company’s stock worth $262,000 after purchasing an additional 1,480 shares during the period. Raymond James Trust N.A. grew its position in Stevanato Group by 22.6% in the 3rd quarter. Raymond James Trust N.A. now owns 12,556 shares of the company’s stock valued at $251,000 after buying an additional 2,317 shares during the last quarter. Finally, First Bank & Trust increased its stake in Stevanato Group by 29.1% in the 3rd quarter. First Bank & Trust now owns 14,109 shares of the company’s stock valued at $282,000 after buying an additional 3,182 shares during the period.

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.